On July 16, 2025, Amgen and Accord settled Case No. 1:25-cv-01305 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) alleging infringement of 34 of Amgen’s patents by Accord’s proposed Prolia® / Xgeva® (denosumab) biosimilar INTP23 (previously reported BPCIA Lawsuit Against Accord’s Proposed Prolia® / Xgeva® Biosimilar Filed by Amgen). In the consent judgment, Accord agreed that all the asserted patents are valid, enforceable, and infringed by INTP23. The parties agreed to enter an injunction against the commercial launch of INTP23 until October 1, 2025, if FDA-approved. The settlement allows market entry prior to the latest expiring asserted patent.
This is the fourth denosumab BPCIA litigation that has been settled (previously reported Amgen and Sandoz Settle Prolia® / Xgeva® Biosimilar Litigation; Celltrion and Amgen Reach Settlement in Prolia® / Xgeva® Biosimilar Litigation; Biosimilar Cases to Watch: Prolia/Xgeva and Denosumab Competitors with The Center for Biosimilars; Prolia® / Xgeva® (denosumab) Biosimilar Updates: Celltrion Biosimilar Approval, Amneal aBLA Filing, and Fresenius Kabi Litigation Settlement). Four other litigations remain ongoing related to Samsung Bioepis’s Ospomyv™ / Xbryk™ (denosumab-dssb) (Case No. 1:24-cv-08417 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.)), Hikma’s RGB-14 (Case No. 1:25-cv-12152 (D.N.J.)), Shanghai Henlius Biotech’s HLX14 (Case No. 1:25-cv-12160 (D.N.J.)), and Biocon’s Bmab 1000 (Case No. 1:25-cv-13358 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.)).
Since June 2025, three denosumab biosimilars have launched in the U.S., including Sandoz’s interchangeable biosimilars Jubbonti® / Wyost® (denosumab-bbdz) (previously reported Sandoz Launches Jubbonti® / Wyost® (denosumab-bbdz) as First Prolia® / Xgeva® Interchangeable Biosimilars), Fresenius Kabi’s Conexxence™ / Bomyntra™ (denosumab-bnht), and Celltrion’s Stoboclo® / Osenvelt® (denosumab-bmwo) (previously reported Fresenius Kabi and Celltrion Launch Prolia® / Xgeva® (denosumab) Biosimilars Conexxence™ / Bomyntra™ and Stoboclo® / Osenvelt®).
Amgen reported FY24 U.S. sales for Prolia® of $2.885 billion, and $1.507 billion for Xgeva®.
For an overview of Prolia® / Xgeva® patent proceedings and aBLAs, please visit Spotlight On: Prolia® / Xgeva® (denosumab) / Jubbonti® / Wyost® (denosumab-bbdz) / Ospomyv™ / Xbryk™ (denosumab-dssb) / Stoboclo® / Osenvelt® (denosumab-bmwo) / Conexxence™ / Bomyntra™ (denosumab-bnht).
_____________________________________________________
The author would like to thank April Breyer Menon for her contributions to this article.
